Cepheid CEO and leadership

David obtained a BA degree in Biochemistry from San Jose State University in 1979, and obtained a combined MD-PhD degree (Medical Scientist Training Program) from the University of California, San Francisco in 1988. His doctoral thesis research on hepatitis B virus was conducted in the Department of Biochemistry & Biophysics under thesis coadvisors Don Ganem and nobel laureate Harold Varmus. He completed his residency in Laboratory Medicine at the Yale University School of Medicine, and then joined the Laboratory Medicine and Pathology Staff at the Mayo Clinic. At Mayo Rochester, he founded the Molecular Microbiology laboratory with the goal of bringing leading-edge molecular diagnostics to the diagnosis of infectious diseases. He also established several extramurally funded research programs to study Lyme disease and other tick-borne infections. In 1999, against the medical advice of his Mayo colleagues, he decided to leave the eternal security of a tenured position and take a walk on the wild side of the biotech. Ultimately as Chief Scientific Officer at Corixa corporation in Seattle, he led several multidisciplinary research teams focused on innate immunity, vaccine development, and molecular diagnostics for infectious diseases and cancer. Corixa was acquired in 2005 by Glaxo Smithkline; he joined Cepheid as Chief Medical and Technology Officer later that year.He has authored over 250 peer-reviewed articles, including several high-impact articles in the New England Journal of Medicine, Science, and the Proceedings of the National Academy of Sciences. He served as Editor-in-Chief for 3 books on molecular diagnostics, and is listed an inventor on more than 20 issued or pending US patents.Specialties: Technology evaluation, strategic planning, market trend assessment, product research and product development, discovery research, predicting the future, creative applications of technology in translational medicine

Dr. Flom was promoted to Senior Vice President, Clinical Affairs and Regulatory Submissions in January 2010 and became our Executive Vice President, Chief Regulatory Officer in January 2013. From May 2004 to January 2010, Dr. Flom served as our Vice President, Clinical Affairs and Regulatory Submissions. Prior to joining Cepheid, Dr. Flom was Senior Director, Clinical Affairs and Regulatory Submission for Abbott Molecular Diagnostics from 2001 to 2004. Prior to Abbott, Dr Flom directed the clinical affairs departments at Vysis, Inc., Baxter Health Corporation – Cardiovascular Group (presently Edwards Lifesciences), and Oncor, Inc. Before joining Oncor, Dr. Flom has held clinical and R&D positions at Boehringer Mannheim Corporation (presently Roche Diagnostics), Behring Diagnostics, and Corning, Corporation.

David obtained a BA degree in Biochemistry from San Jose State University in 1979, and obtained a combined MD-PhD degree (Medical Scientist Training Program) from the University of California, San Francisco in 1988. His doctoral thesis research on hepatitis B virus was conducted in the Department of Biochemistry & Biophysics under thesis coadvisors Don Ganem and nobel laureate Harold Varmus. He completed his residency in Laboratory Medicine at the Yale University School of Medicine, and then joined the Laboratory Medicine and Pathology Staff at the Mayo Clinic. At Mayo Rochester, he founded the Molecular Microbiology laboratory with the goal of bringing leading-edge molecular diagnostics to the diagnosis of infectious diseases. He also established several extramurally funded research programs to study Lyme disease and other tick-borne infections. In 1999, against the medical advice of his Mayo colleagues, he decided to leave the eternal security of a tenured position and take a walk on the wild side of the biotech. Ultimately as Chief Scientific Officer at Corixa corporation in Seattle, he led several multidisciplinary research teams focused on innate immunity, vaccine development, and molecular diagnostics for infectious diseases and cancer. Corixa was acquired in 2005 by Glaxo Smithkline; he joined Cepheid as Chief Medical and Technology Officer later that year.He has authored over 250 peer-reviewed articles, including several high-impact articles in the New England Journal of Medicine, Science, and the Proceedings of the National Academy of Sciences. He served as Editor-in-Chief for 3 books on molecular diagnostics, and is listed an inventor on more than 20 issued or pending US patents.Specialties: Technology evaluation, strategic planning, market trend assessment, product research and product development, discovery research, predicting the future, creative applications of technology in translational medicine

Dr. Flom was promoted to Senior Vice President, Clinical Affairs and Regulatory Submissions in January 2010 and became our Executive Vice President, Chief Regulatory Officer in January 2013. From May 2004 to January 2010, Dr. Flom served as our Vice President, Clinical Affairs and Regulatory Submissions. Prior to joining Cepheid, Dr. Flom was Senior Director, Clinical Affairs and Regulatory Submission for Abbott Molecular Diagnostics from 2001 to 2004. Prior to Abbott, Dr Flom directed the clinical affairs departments at Vysis, Inc., Baxter Health Corporation – Cardiovascular Group (presently Edwards Lifesciences), and Oncor, Inc. Before joining Oncor, Dr. Flom has held clinical and R&D positions at Boehringer Mannheim Corporation (presently Roche Diagnostics), Behring Diagnostics, and Corning, Corporation.

David obtained a BA degree in Biochemistry from San Jose State University in 1979, and obtained a combined MD-PhD degree (Medical Scientist Training Program) from the University of California, San Francisco in 1988. His doctoral thesis research on hepatitis B virus was conducted in the Department of Biochemistry & Biophysics under thesis coadvisors Don Ganem and nobel laureate Harold Varmus. He completed his residency in Laboratory Medicine at the Yale University School of Medicine, and then joined the Laboratory Medicine and Pathology Staff at the Mayo Clinic. At Mayo Rochester, he founded the Molecular Microbiology laboratory with the goal of bringing leading-edge molecular diagnostics to the diagnosis of infectious diseases. He also established several extramurally funded research programs to study Lyme disease and other tick-borne infections. In 1999, against the medical advice of his Mayo colleagues, he decided to leave the eternal security of a tenured position and take a walk on the wild side of the biotech. Ultimately as Chief Scientific Officer at Corixa corporation in Seattle, he led several multidisciplinary research teams focused on innate immunity, vaccine development, and molecular diagnostics for infectious diseases and cancer. Corixa was acquired in 2005 by Glaxo Smithkline; he joined Cepheid as Chief Medical and Technology Officer later that year.He has authored over 250 peer-reviewed articles, including several high-impact articles in the New England Journal of Medicine, Science, and the Proceedings of the National Academy of Sciences. He served as Editor-in-Chief for 3 books on molecular diagnostics, and is listed an inventor on more than 20 issued or pending US patents.Specialties: Technology evaluation, strategic planning, market trend assessment, product research and product development, discovery research, predicting the future, creative applications of technology in translational medicine